Tarlatamab Prolongs OS Over Chemotherapy Among Patients with SCLC Whose Disease Had Progressed During or After Platinum-Based Chemotherapy By Ogkologos - June 16, 2025 626 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the DeLLphi-304 study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Allogeneic Regulatory T Cell-Based Immunotherapy with HSPC and T Cells-vldq for Use in Matched Donor HSCT for Adult Patients with Haematologic Malignancies Combination of mFOLFOX6/Bevacizumab Plus Atezolizumab Prolongs PFS Compared with Atezolizumab in First-Line Treatment of dMMR/MSI-H mCRC Use of YEARS Algorithm, D-dimer Levels, and Performing Risk-Dependent CT Pulmonary Angiography is Safe in Patients with Cancer and Suspected Pulmonary Embolism MOST POPULAR Race for Life events are back this autumn June 25, 2021 Breast Cancer Survivors Are Still Underrepresented At Victoria’s Secret February 1, 2022 Ivonescimab Plus Chemotherapy Significantly Improves PFS in Patients with NSCLC Previously... June 19, 2024 Can Artificial Intelligence Help See Cancer in New, and Better, Ways? March 22, 2022 Load more HOT NEWS Neoadjuvant ICI Without Chemotherapy Demonstrates Potential Efficacy in Patients with Early-Stage... This Common Antibiotic May Help Support Immune System in Cancer Patients... Mom Gives Birth and Receives a Breast Cancer Diagnosis on the... Υποτροπιάζων ή μεταστατικός καρκίνος κεφαλής και τραχήλου: Νέα δεδομένα αναμένεται ότι...
